Compare Newmont Corporation (NEM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs GeneDx Holdings Corp — how do they compare? Newmont Corporation trades at $117.84 (market cap $121.75B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Newmont Corporation is far larger — about 60.3× GeneDx Holdings Corp's market cap, and Newmont Corporation pays a 0.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and GeneDx Holdings Corp for 19 Days on average.
| NEM | WGS | |
|---|---|---|
Market Cap | $121.75B | $2.02B |
Volume | 5,421,125 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $167.51 |
52-Week Low | $78.63 | $34.51 |
Typical Hold Time | 58 Days | 19 Days |
Enterprise Value | $118.34B | $2.05B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $115.55, up 1.77% today, with a bearish technical signal despite strong fundamentals. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025, with net income margin expanding to 33.36%.
Outlook remains positive with a consensus price target of $136.83, implying 18% upside, supported by operational improvements and favorable gold prices. Risks include gold price volatility and execution of growth projects. Analyst sentiment is strongly bullish with 76% buy ratings and no sell recommendations.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
